Login to Your Account

Beigene's PD-1 antibody gets clinical study approval in China

By Shannon Ellis
Staff Writer

Monday, September 12, 2016

SHANGHAI – China's regulatory authorities have given Beigene Co. Ltd., the green light to study BGB-A317, a fully human PD-1 antibody, on patients in China.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription